Clinical Trials
2.9k
Active:472
Completed:1181
Trial Phases
6 Phases
Early Phase 1:76
Phase 1:722
Phase 2:1004
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2410 trials with phase data)β’ Click on a phase to view related trials
Phase 2
1004 (41.7%)Phase 1
722 (30.0%)Not Applicable
477 (19.8%)Phase 3
102 (4.2%)Early Phase 1
76 (3.2%)Phase 4
29 (1.2%)Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Not Applicable
Not yet recruiting
- Conditions
- Large B-cell LymphomaHodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT07164469
- Locations
- πΊπΈ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Together Stronger: A Family-centered Lifestyle Intervention for Black Prostate Cancer Survivors and Their Caregivers
Not Applicable
Not yet recruiting
- Conditions
- Family CenteredBlack EthnicityProstate Cancer Survivors
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 648
- Registration Number
- NCT07164456
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)
Not Applicable
Not yet recruiting
- Conditions
- Adenoid Cystic Carcinoma
- Interventions
- Drug: P-Sam
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT07162480
- Locations
- πΊπΈ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Not Applicable
Not yet recruiting
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT07153796
- Locations
- πΊπΈ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Evaluation of Meaning-centered Group Psychotherapy in Integrative Medicine
Not Applicable
Not yet recruiting
- Conditions
- PsychotherapyIntegrative Medicine
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT07147205
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 582
- Next
News
No news found